Between cost pressure and quality standards: How consolidated platforms are changing autoimmune diagnostics

Autoimmune diseases are no longer a marginal phenomenon — they have become a structural driver of test volume, complexity, and costs in medical laboratories. For institutions in the DACH region, the question is no longer whether autoimmune diagnostics are changing, but how quickly laboratories are responding to this change.

The epidemiological data is clear: in Germany, the prevalence of diagnosed autoimmune diseases rose from 7.06% to 8.61% between 2012 and 2022 – a relative increase of 22%. This means that in 2022, more than 6.3 million people with statutory health insurance were affected, or about one in twelve people [2,3].

In Austria, the number of people affected is estimated at around 700,000 (up to 8% of the population) [4]. Autoimmune diseases are also widespread in Switzerland; Hashimoto's thyroiditis in particular affects almost one in ten people, and there are also tens of thousands of patients with rheumatoid arthritis or multiple sclerosis [5,9].

For laboratories in Germany, Austria, and Switzerland, this development means not only a higher sample volume, but above all growing diagnostic complexity—accompanied by increasing economic pressure. Autoimmune diseases now affect almost all clinical disciplines: rheumatology, endocrinology, gastroenterology, nephrology, and neurology. Accordingly, the demands on the sensitivity, speed, and breadth of laboratory diagnostics are growing.

A key strategic response to this is the consolidation of diagnostic platforms that combine routine and specialized diagnostics in a single system.

 

The silent epidemic in the DACH region

Autoimmune diseases such as Hashimoto's thyroiditis, rheumatoid arthritis, psoriasis, celiac disease, and systemic lupus erythematosus (SLE) are no longer a niche topic. In addition to the absolute increase in the number of cases, it is particularly relevant that diagnoses are increasingly affecting younger patient groups. Clinical data and experience reports from the DACH region indicate a shift in initial diagnoses to age groups under 40 [4,5].

This has several consequences for laboratories:

• Broader test panels are becoming the standard, not the exception.
• Early diagnosis is becoming increasingly important, especially for non-specific symptoms such as fatigue, arthralgia, or subclinical inflammation.
• Serial follow-up checks are becoming more frequent, for example in chronic inflammatory diseases.

Fragmented device structures—separate systems for hormones, tumor markers, infection serology, and autoimmune parameters—are increasingly reaching their limits under these conditions.

 

The outsourcing dilemma: when relief becomes a cost trap

In many medium-sized laboratories, a significant proportion of autoimmune diagnostics continues to be outsourced to external service providers, especially for ANA and ENA profiles. This practice has often developed over time – for example, through separate device structures for routine parameters and special diagnostics.

In practice, however, this leads to several disadvantages:

• Costs: External analyses are on average significantly more expensive than internal ones. Model calculations from laboratory practice show considerable additional costs per test when logistics and overheads are taken into account.
• Turnaround time (TAT): While internal results are often available within 6–24 hours, TAT is extended to 48–72 hours or longer when outsourcing.
• Process effort: Shipping, sample stability, interfaces, queries, and documentation increase the organizational effort and susceptibility to errors.

For a medium-sized laboratory, this can lead to additional annual costs in the five-digit range—in addition to the clinical disadvantages of delayed findings, for example in rheumatological or vasculitic issues.

 

Role of autoantibody diagnostics

Laboratory diagnostics of autoimmune diseases relies heavily on the detection of specific autoantibodies. Antinuclear antibodies (ANA) and ENA profiles are used to diagnose ANA-associated rheumatic diseases such as systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, or inflammatory myopathies. In addition, there are organ-specific autoantibodies, for example against thyroid, pancreatic, or hepatic structures, which are highly relevant for the diagnosis of Hashimoto's thyroiditis, type 1 diabetes, or autoimmune hepatitis.

A step-by-step approach with screening (e.g., indirect immunofluorescence on HEp-2 cells) followed by specification using immunoassays such as ELISA, chemiluminescence assays, or line blots is established diagnostically. In many cases, autoantibodies can be detected years before clinical manifestation, enabling early classification of nonspecific symptoms and close monitoring of the course of the disease [10].

 

Consolidation as a strategic approach

Consolidated laboratory platforms that map both high-throughput routine parameters and specialized autoimmune assays on a single system offer a structural solution. Modern CLIA (chemiluminescence immunoassay) platforms now enable the parallel determination of routine parameters such as TSH, fT4, 25-OH vitamin D, PSA, PCT, or IL-6 and, at the same time, complex autoantibody profiles.

Modern CLIA platforms such as the MAGLUMI series from Snibe Diagnostics are examples of this approach. These systems are designed to map routine parameters and specialized autoimmune markers within a uniform platform. With test menus of over 260 parameters—including ANA, ENA, and ANCA profiles as well as organ-specific autoantibodies—they represent the trend toward functional and structural consolidation in laboratory diagnostics [6,7].

Technologically, such systems are based on chemiluminescent detection methods in combination with magnetic micro- or nanobeads, which enable high analytical sensitivity and specificity. Manufacturer data show very good agreement with established reference methods such as IFA, ELISA, or line blot methods [8].

This results in several advantages for laboratories:

• Insourcing instead of outsourcing: A large part of autoimmune diagnostics can be performed in-house again.
• Reduced TAT: Special parameters are available in hours instead of days.
• Cost efficiency: Elimination of external fees, reduced logistics, and bundled maintenance.
• Standardized workflows: One system, one quality management system, one training concept.
• Scalability: Growing test volumes can be better accommodated.

 

Future prospects: Autoimmune diagnostics in a consolidated laboratory

The global market for autoimmune diagnostics is estimated to exceed USD 10 billion by 2032, with an annual growth rate of around 7% [1]. For laboratories in the DACH region, this means above all: further increases in test volumes, a growing variety of markers, and increasing demands on throughput, availability, and cost-effectiveness.

Against this backdrop, consolidated CLIA platforms are becoming increasingly important. Developments in laboratory medicine are focused less on disruptive technological change and more on:

• the continuous expansion of existing test menus, particularly in the field of autoimmunity,
• the integration of additional markers into existing workflows,
• higher automation and throughput rates within established platform architectures,
• and even closer integration of routine and specialized diagnostics.

For laboratories, this means that systems that already combine routine parameters and autoimmune assays on a single platform today form the structural basis for future growth. They make it possible to integrate new markers without additional equipment structures, further reduce outsourcing, and handle increasing volumes with stable processes.

 

Conclusion

The consolidation of autoimmune diagnostics is more than a technical trend—it is a strategic response to:

• increasing prevalence in Germany, Austria, and Switzerland,
• growing cost pressure,
• higher demands on quality and speed,
• increasing complexity of diagnostics.

Laboratories that critically examine their outsourcing rates and rely on integrated platforms strengthen their economic position while making a measurable contribution to faster and more precise care for patients with autoimmune diseases throughout the DACH region.

 

Literature & Sources

1. Market.us (2024). Autoimmune Disease Diagnostics Market – Global Forecast.
https://market.us/report/autoimmune-disease-diagnostics-market/

2. Akmatov MK et al. (2024). Entwicklung der Prävalenz diagnostizierter Autoimmunerkrankungen im Zeitraum 2012–2022. Zi, Versorgungsatlas Nr. 24/05. DOI: 10.20364/VA-24.05

3. Deutsches Ärzteblatt (2024). Prävalenz von Autoimmunerkrankungen gestiegen.

4. Geroldinger-Simić M. (2021). Autoimmunerkrankungen: „Die größte Herausforderung ist eine frühzeitige Diagnose“. medinlive.

5. Universitätsspital Zürich (2025). Autoimmun-Erkrankungen treten häufiger auf als man denkt.

6. Snibe Diagnostics. MAGLUMI Product Portfolio. https://www.snibe.com

7. Snibe Diagnostics. MAGLUMI CLIA Test Menu – Autoimmune Panel.
https://www.snibe.com/en/product/CLIA_menu/

8. Snibe Diagnostics. MAGLUMI ABEI-Technologie – Leistungsdaten.

9. Sanitas Schweiz (2025). Autoimmunerkrankungen: Die häufigsten Formen erklärt.

10. IMD Berlin. Autoimmundiagnostik: Frühzeitige Erkennung entscheidend für Therapieerfolg.

11. Hans-Böckler-Stiftung (2016). Branchenanalyse Laboranalytik in Deutschland.